Status:
COMPLETED
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Glioblastoma
Eligibility:
All Genders
Brief Summary
The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care ...
Detailed Description
Participant sampling method: consecutive patient sampling.
Eligibility Criteria
Inclusion
- Newly diagnosed Glioblastoma multiforme
Exclusion
- History of hypersensitivity to temozolomide or its components, or to dacarbazine.
- Women who are pregnant or breast-feeding.
- Patients with severe myelosuppression.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00725010
Start Date
April 1 2007
End Date
April 1 2009
Last Update
September 9 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.